Overview

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Status:
NOT_YET_RECRUITING

Trial end date:
2028-02-29

Target enrollment:

Participant gender:

Summary

To evaluate the tolerability and safety of Low-dose radiotherapy combined with concurrent Chemotherapy, Toripalimab and Tifcemalimab in first-line treatment of Extensive-Stage Small Cell Lung Cancer, and to determine the RP2D.

Phase:

PHASE1

Details

Lead Sponsor:

Sichuan University

Treatments:

Carboplatin
Cisplatin
Etoposide
Radiotherapy
toripalimab